Gencet

Quick links to important sections

Gencet

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gencet

Property Description
Active Ingredient Cetirizine Hydrochloride
Form Tablet and Oral Solution (or Syrup)
Pharmacological Class Second-generation H₁-receptor antagonist
General Purpose Relief from allergic conditions
Origin Synthetic, Piperazine derivative

Gencet: Classification and Core Identity

Gencet is a synthetic medication whose active component is Cetirizine Hydrochloride, primarily categorized as a second-generation antihistamine. It functions as an H₁-receptor antagonist, meaning it works to block the action of histamine, the key chemical released by the body during an allergic reaction. This compound is a metabolite of hydroxyzine, and its effectiveness as a histamine blocker is used for managing symptoms related to common allergic events.


Composition, Forms, and General Purpose

The general purpose of Gencet is to provide relief from the symptoms associated with allergic responses by blocking the action of histamine. This medication is administered via the oral route and is typically available as a single-ingredient product, offered in two primary dosage forms: the Tablet and a liquid Oral Solution (or syrup). The availability of the oral solution form positions Gencet as a suitable choice for pediatric patients or adults who prefer a liquid administration. Cetirizine is indicated for the management of symptoms of allergic conditions.


How Gencet Differs from Other Antihistamines

Gencet, consistent with its classification as a second-generation antihistamine, is designed to offer allergy relief with a significantly lower potential for inducing sedation when compared to older treatments. This distinction is due to the drug's selective peripheral action, minimizing its ability to cross the blood-brain barrier. Second-generation H₁-antihistamines, including cetirizine, are associated with a reduced risk of central nervous system effects such as sleepiness. This property supports the management of allergic symptoms throughout the day without the common sedative effects of first-generation agents.

Regulatory References

  1. NIH MedlinePlus Drug Information: Cetirizine (Oral)

What side effects are possible with Gencet?

Possible side effects and safety information

The safety profile for Gencet (Cetirizine Hydrochloride) is officially documented by regulatory authorities, classifying possible adverse reactions primarily by frequency and the body system affected. These classifications dictate how often an effect is reported in clinical use and post-marketing surveillance.

Reactions classified as Common (ge1/100 to <1/10) primarily affect the nervous and gastrointestinal systems. These include officially listed effects such as somnolence, fatigue, headache, dizziness, dry mouth, nausea, and pharyngitis. Less frequently reported effects, listed as Uncommon, include agitation, paresthesia, pruritus, and rash.

Documented Serious Adverse Reactions

Serious adverse reactions are documented within the Rare and Very Rare frequency categories. Rare (ge1/10,000 to <1/1,000) effects include hypersensitivity, convulsions, tachycardia, and abnormal hepatic function, which is usually reversible upon discontinuation. Very Rare (<1/10,000) effects include severe systemic reactions such as anaphylactic shock, angioneurotic oedema, and thrombocytopenia.

Population-Specific Safety Considerations

Specific caution is advised in certain populations as detailed in regulatory labeling. Individuals with renal impairment or hepatic impairment may require consideration for dose adjustment due to the potential for reduced drug excretion. Caution is also recommended in older adults, where excretion may be reduced, and in patients with factors predisposing them to urinary retention. Furthermore, post-marketing reports document the potential for intense pruritus and/or urticaria upon the discontinuation of the medicine, especially after long-term daily use.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Gencet

Overdose Scope

Feature Official Regulatory Statements for Cetirizine Overdose
Documented overdose presentations Primarily CNS depression symptoms, including somnolence, sedation, and fatigue. Other reported manifestations include headache, diarrhea, dizziness, confusion, and, in some cases, symptoms suggestive of an anticholinergic effect, such as mydriasis (dilated pupils).
Physiological systems affected Central Nervous System, Gastrointestinal, and Cardiovascular (risk of tachycardia).
Dose-related or exposure-related factors Symptoms of overdose have been observed following ingestion of five times or more the maximum recommended daily dose.
Population-specific overdose notes Overdose in pediatric patients may present initially as restlessness and irritability before the onset of drowsiness. Older adults are also noted to be at a higher risk for severe symptoms.
Emergency-response statements Management is symptomatic and supportive, as no specific antidote is known. Measures like gastric lavage and the administration of activated charcoal may be considered.
When immediate medical help is required Urgent medical attention is required for severe manifestations, including collapse, trouble breathing, seizure, or the inability to be awakened. The Poison Control Center should be contacted right away in any case of suspected overdose.

Overdose Classifications (High-Level)

Feature Official Regulatory Statements
Severity classification Overdose may result in serious neurological and cardiovascular complications, such as convulsions and tachycardia.
Regulatory basis Based on official information documented in government prescribing guidelines.
Overdose-context constraints The substance is not effectively removed from the body by dialysis. Cardiac monitoring may be necessary in the management of large ingestions.

Resulting Overdose Structure

Official overdose statements:

  • Overdose is primarily characterized by CNS effects such as somnolence and sedation, but may involve serious outcomes like convulsions and tachycardia.
  • Immediate medical attention is required for severe symptoms, including seizure, collapse, or inability to be awakened.
  • The official management strategy is supportive care, as no specific antidote is known.

Connection to the overall overdose profile (3 sentences): Government regulatory documents define the overdose profile by a spectrum of CNS and systemic manifestations that are typically observed after ingesting a high multiple of the recommended dose. The potential for serious, documented outcomes establishes the specific conditions under which regulators mandate immediate emergency help-seeking. Management procedures are limited to supportive care and specific decontamination measures, consistent with the stated absence of a specific neutralizing agent.

Therapeutic Uses of Gencet

What Gencet Treats: Main Uses and Benefits

Gencet (Cetirizine Hydrochloride) is applied across domains where additional symptomatic support is needed to address allergic conditions. It is commonly used in contexts marked by increased discomfort due to symptoms related to inflammatory or irritative states. The application of this medication is relevant across therapeutic domains involving heightened symptomatic responses.

The medication is relevant for easing symptoms that create noticeable physiological strain, which typically includes seasonal and perennial allergic rhinitis, chronic urticaria, and allergic conjunctivitis. Specifically, it addresses symptom clusters such as frequent sneezing, runny nose (rhinorrhea), itchy nasal passages, and symptoms related to itchy, watery, and red eyes.

“It is helpful in situations where symptoms may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms.”

Furthermore, Gencet is applied in addressing the symptoms of allergic skin manifestations (hives), offering symptomatic relief from intense skin itching (pruritus).

Quick Fact: Relief for Allergic Skin Symptoms

The medication is commonly used across conditions presenting with acute or disruptive episodes of chronic urticaria (hives). This provides supportive relief that assists with maintaining functional stability.

Regulatory References

  1. UK Summary of Product Characteristics

Eligibility and Restrictions for Use

Who can and cannot use Gencet?

Eligibility for Gencet (Cetirizine Hydrochloride) is governed by specific criteria defined in official regulatory documents, outlining who is approved for use and who must be excluded.

Eligibility Scope

Classification Population Status (Official Labeling)
Populations for whom use is allowed Adults and adolescents (ge 12 years). Children aged 6 years and older (tablets/solutions); children aged 2 to 5 years (liquid solutions only).
Populations for whom use is contraindicated Patients with known hypersensitivity to cetirizine, hydroxyzine, or any piperazine derivatives. Individuals with severe renal impairment (Creatinine Clearance < 10 ml/min).

Eligibility-Related Restrictions

  • Condition-specific eligibility rules: Use is restricted and requires dose adjustment in patients with moderate renal impairment or hepatic impairment. The tablet form is not recommended for children under 6 years of age.
  • Pregnancy and lactation eligibility: Use is restricted; caution is recommended for pregnant and lactating individuals as the substance is known to be excreted into human milk.
  • Conditional use: Caution is formally advised for older adults and in patients with predisposing factors for conditions like urinary retention or epilepsy, as noted in regulatory labeling.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use Gencet by establishing clear exclusions based on absolute contraindications, such as severe renal failure, and formal limitations tied to age thresholds. Eligibility status progresses to conditional use when organ function is compromised or physiological caution is required, ensuring all restrictions are strictly based on the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Gencet (Cetirizine Hydrochloride) is officially documented by regulatory authorities, focusing on both how other substances affect its concentration and how it interacts with the central nervous system (CNS).

Pharmacodynamic and Substance Interactions

Co-administration with Central Nervous System (CNS) depressants, such as tranquilizers or sedatives, may lead to an additive impairment of CNS performance and a greater reduction in alertness, as noted in official prescribing information. Concurrent use with Alcohol (Ethanol) is also advised against by regulatory labels due to the potential for additional reduction in alertness and impairment of performance.

Pharmacokinetic and Exposure Alterations

  • Theophylline: Co-administration of 400 mg of Theophylline daily has been shown to cause a 16% decrease in the clearance of cetirizine, which increases the drug’s overall systemic exposure.
  • Ritonavir: This medicine causes an increase in the plasma concentration of cetirizine, confirming a pharmacokinetic interaction where the drug's metabolism or elimination is altered.
  • Food: Food intake is officially documented to delay the time to peak plasma concentration (Tmax) but does not reduce the total extent of absorption (AUC).

Population-Specific Interaction Notes

Official labeling indicates that patients with renal impairment will have reduced clearance of the drug. This decrease in elimination leads to an increased systemic exposure to the medication, which may necessitate adjustments outside the scope of this interaction summary.

Mechanism of Action

Targeted Blockade of Peripheral H1 Receptors

Gencet operates by selectively and competitively binding to the Histamine H1 receptors found on cells in peripheral tissues, acting as an antagonist to block the signal initiated by released histamine. This molecular intervention immediately engages mechanisms that regulate pathway activity, resulting in the blockade of histamine-mediated signal transduction.

Modulation of Vascular Permeability

By preventing H1 receptor activation, the drug modifies early molecular steps that preserve the stability of blood vessel walls, ensuring normal vascular integrity and restricting changes in capillary permeability. This mechanism is primarily relevant in peripheral systems, supporting the modulation of processes driven by histamine to curtail fluid leakage into the surrounding tissues, which is a key driver of tissue edema.

Peripheral Focus and Secondary Cell Modulation

Due to the drug's properties, its mechanism is highly focused on peripheral pathways, restricting interaction with central pathways. Beyond the receptor, the molecule engages secondary mechanisms that influence the chemotaxis and activity of inflammatory cells like eosinophils, contributing to the attenuation of the physiological response by influencing the cellular component of the inflammation cascade.

Dosage and Administration Information

How Gencet is Used: Official Administration Guidelines

Administration of Gencet (Cetirizine Hydrochloride) follows specific protocols regarding route, dosage, and scheduling. The medication is primarily available for oral use as a tablet or solution/syrup, which is the standard administration method for outpatient use. The active ingredient is also approved for intravenous (IV) administration as an injection.

Dosing and Frequency Patterns

The standard oral regimen for adults and adolescents (aged 12 years and older) is 10 mg once daily. Pediatric regimens vary by age, such as 5 mg taken twice daily or 10 mg once daily for children aged 6 to 11 years. The intravenous dose is typically 10 mg once every 24 hours for patients aged 12 years and older, administered as a slow IV push over a period of 1 to 2 minutes.

Administration Condition Standard Parameters
Timing in Relation to Food May be taken with or without food; the overall amount absorbed is not affected.
Renal Impairment Dose adjustments are mandatory for adults with reduced kidney function (creatinine clearance < 50 mL/min).
Missed Dose If a scheduled dose is missed, it should be skipped; do not take a double dose to compensate.

These parameters describe the standardized approach to the use of the medication.

Recent Clinical Evidence

Gencet: Recent Clinical Evidence


Evidence for Use in Seasonal and Perennial Allergic Rhinitis

Research has evaluated Gencet in studies exploring conditions characterized by fluctuating or episodic manifestations, specifically allergic rhinitis, including both seasonal (hay fever) and perennial (year-around) allergies. These studies primarily involve short-term, Randomized Controlled Trials (RCTs) that compared the effects on symptoms against a placebo or other active comparator agents. Studies explored patient-reported experiences by monitoring various outcomes related to physical discomfort, such as sneezing, rhinorrhea (runny nose), and itching. The evidence base consists primarily of controlled trials that were utilized in regulatory review and applies to trials assessing short-term or episodic symptom patterns.


Evidence for Use in Chronic Urticaria (Hives) and Allergic Skin Symptoms

Studies focused on episodes where symptoms become more noticeable in allergic skin manifestations, such as chronic urticaria (hives), in which Gencet was evaluated. This research mainly used short-term RCTs, tracking primary metrics related to the severity of pruritus (itching) and the size or number of wheals (hives). Studies reported patterns of change in these measured outcomes related to physical discomfort within the observed populations. Certain trials also explored the evaluation of the medication in patients with severe symptoms who were unresponsive to standard treatment, although the data show patterns related to higher doses only in settings with varying symptom burdens.


Evidence Gaps and Areas of Research Uncertainty

A key limitation in the research is the focus on short-term outcomes and acute symptom monitoring. Long-term effects are not fully established, and there is limited information concerning the durability of any observed patterns over many months or years. Additionally, data for certain special groups remain insufficient. For example, evidence remains limited for the youngest children (under two years old), and comparative evidence is often lacking from trials directly comparing Gencet against many available current treatment options.

Key Studies & References

  1. Cetirizine Hydrochloride Label and Monograph - FDA DailyMed

Frequently Asked Questions (FAQ)

Common questions about Gencet (FAQ)

Q: Does Gencet interact with over-the-counter pain relievers?

Regulatory documents primarily warn against concurrent use with Central Nervous System (CNS) depressants and alcohol due to the potential for additive effects. However, official information does not specifically list common over-the-counter pain relievers, like ibuprofen or acetaminophen, as having a defined pharmacokinetic interaction.

Q: What happens if I miss a scheduled dose of Gencet?

Official instructions concerning administration advise that if a scheduled dose is missed, it should be skipped entirely. Official documents state the recommendation is not to take a double or extra dose to compensate for the missed one.

Q: Can Gencet be taken with antacids or heartburn medication?

Regulatory documents do not specifically list common antacids or heartburn medications as having a defined pharmacokinetic interaction. The primary interactions listed are with Central Nervous System depressants and certain medications that can affect its clearance.

Q: Is it normal to feel a little tired when first taking Gencet?

Yes, official regulatory labeling describes somnolence (drowsiness) and fatigue as frequently reported effects. These are classified as Common adverse reactions, meaning they are reported in between 1 out of 100 to less than 1 out of 10 patients in clinical settings.

Q: What percentage of people experience the major reported side effects of Gencet?

Regulatory documents classify the frequency of side effects using general categories rather than providing exact percentages. Effects are often listed as Common (reported in ge 1/100 to < 1/10 of patients) or Uncommon (reported in ge 1/1,000 to < 1/100 of patients) to indicate how frequently they occur.

Q: Can women who are planning pregnancy use Gencet?

Official documents contain a formal cautionary statement regarding use during pregnancy, and its use is generally advised against during the final trimester. The regulatory labeling also notes that the substance is known to be excreted into human milk.

Q: How long does it usually take to feel the effects of Gencet?

Studies and official sources indicate that the drug typically begins to work quickly. The onset of action is typically reported within one hour of taking the oral administration form.

Q: Does Gencet cause weight gain or loss?

While regulatory labeling provides an extensive list of reported adverse reactions, the official frequency categories (Common or Uncommon) of reported effects do not list weight gain or loss.

Q: Can older adults generally use Gencet?

Official labeling contains a formal cautionary statement regarding use in older adults. This is due to the potential for reduced drug excretion in this population, which may require consideration for dose adjustments.

Q: How quickly does Gencet leave the body?

The time it takes for half the drug to be eliminated (the elimination half-life) is officially described as approximately 8 to 11 hours in healthy adults.

Q: Is there a generic version of Gencet available?

Yes, regulatory databases and patient information confirm that the active ingredient in Gencet, Cetirizine Hydrochloride, is available in numerous generic forms from different manufacturers.

Q: How long is the usual treatment period with Gencet?

Official documents define dosing regimens for chronic (year-round) use and intermittent (seasonal) use, but they do not specify a mandatory or usual maximum duration of treatment for the drug.

Q: Does Gencet interact with common supplements like Vitamin D or Omega-3?

Official documents do not list any specific known pharmacokinetic or pharmacodynamic interactions between the drug and common vitamin or fish oil supplements, such as Vitamin D or Omega-3.

Q: Is it necessary to have routine lab tests while taking Gencet?

Regulatory documents do not generally require routine laboratory monitoring for patients taking this drug. However, special monitoring may be necessary if a patient has pre-existing conditions, such as known renal or hepatic impairment.

Q: Does Gencet need to be taken with food?

Official guidance confirms that the drug may be taken with or without food. Food intake has been documented to delay the time it takes for the drug to reach peak concentration, but it does not affect the overall amount of the drug absorbed.

Q: Are there any restrictions on driving or operating machinery while using Gencet?

Regulatory labeling includes a specific warning advising patients to use caution when performing potentially hazardous tasks, such as driving or operating heavy machinery, due to the potential for drowsiness.

Q: Are headaches a common concern when taking Gencet?

Yes, regulatory labeling describes headache as a frequently reported effect in clinical trials. It is classified as a Common side effect.

Q: Can Gencet be crushed or split if it is a tablet?

Official instructions state the drug is administered as an oral tablet or solution. In the absence of an explicit regulatory instruction for crushing or splitting, it is described as being available in these fixed-dose oral forms.

Q: What patient population was Gencet originally studied in?

Clinical development and regulatory approval was based on studies primarily conducted in adult and adolescent populations.

Q: Is Gencet a drug that requires gradual stopping, or can it be stopped abruptly?

Regulatory documents include information that post-marketing reports have described intense itching (pruritus) and/or hives (urticaria) upon abrupt discontinuation, especially after long-term daily use.

Q: Are there different brand names for the same medicine as Gencet?

Yes, official sources confirm that the active ingredient, Cetirizine Hydrochloride, is marketed globally under multiple different brand names, in addition to generic forms.

Q: Do people develop tolerance to Gencet over time?

Regulatory documents describe the drug's efficacy profile, noting its sustained effect in long-term studies for conditions such as perennial allergic rhinitis. This clinical observation suggests a sustained effect based on studies for chronic use.

Q: What if I'm taking multiple prescriptions; does Gencet commonly interact with many drugs?

Regulatory labeling specifies interactions with only a limited number of other medications. The main focus is on drugs that affect the Central Nervous System (CNS depressants) or those that can alter the drug's clearance in the body, such as Theophylline and Ritonavir.

Q: Is the effect of Gencet immediate or does it build up over weeks?

Official sources state that the drug typically begins to work quickly, with effects are typically reported within one hour of oral administration, and it is not described as a medication that requires several weeks to build up to a therapeutic level.

Q: Does Gencet cause any mental or mood side effects?

Regulatory labeling lists certain mental or mood-related effects as documented adverse reactions. These include effects like agitation, dizziness, and somnolence (drowsiness).

Q: Are children or adolescents generally eligible to take Gencet?

Official documents define specific eligibility based on age. Eligibility is specified for children aged 6 years and older (tablets/solutions) and for children aged 2 to 5 years (liquid solutions only).

Q: Where can I find the official regulatory documents for Gencet?

Official documents, such as the Prescribing Information (often found on DailyMed/FDA) and the Summary of Product Characteristics (EMA), are published on the websites of government drug regulatory authorities.

Q: What are the rare but serious side effects of Gencet?

Regulatory labeling documents serious reactions in the Rare and Very Rare frequency categories. These can include severe systemic reactions such as anaphylactic shock, convulsions, and reversible abnormal hepatic function.

Q: Does Gencet have a 'Black Box Warning'?

Official regulatory documents do not include a Black Box Warning, which is the FDA's strongest warning, on the prescribing information for the single-ingredient formulation.

Q: Is Gencet related to any older, discontinued medicines?

Official sources describe the drug as being a metabolite of the first-generation antihistamine hydroxyzine. This describes the chemical relationship between the two compounds.

Q: Are there any known genetic factors that influence how Gencet works?

Regulatory documents do not currently contain specific information detailing genetic factors that are known to significantly influence the drug's pharmacokinetics (how the body processes it) or individual response.

How should Gencet be stored and disposed of?

Gencet (cetirizine hydrochloride and pseudoephedrine hydrochloride) must be stored strictly according to regulatory mandates to maintain its stability and effectiveness.

Official Storage and Handling

Requirement Classification
Temperature Controlled Room Temperature: 20 to 25 C (68 to 77 F)
Handling Preserve in well-closed containers; avoid high humidity and heat.
Protection Keep out of the sight and reach of children (a mandatory safety requirement).
Integrity Do not use if the blister unit is torn or broken or the bottle seal is open.

Official Disposal Instructions

Unused or expired Gencet is not on the FDA flush list. Disposal must prioritize using drug take-back programs or mail-back envelopes. If these options are unavailable, the medication must be removed from its packaging, mixed with an undesirable substance (like coffee grounds or dirt), placed in a sealed container, and discarded in the household trash. Personal information must be scratched out on all empty packaging before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Gencet found in:

A-Z Index: